Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.26080/fullpdf
Reference20 articles.
1. Cancer statistics, 2009;Jemal;CA Cancer J Clin.,2009
2. Long term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresectable NSCLC: RTOG 9410 [abstract];Curran;Proc Am Soc Clin Oncol.,2003
3. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer;Furuse;J Clin Oncol.,1999
4. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 study;Fournel;J Clin Oncol.,2005
5. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B non-small-cell lung carcinoma;Socinski;Cancer.,2001
Cited by 160 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Recommendations for Post-Operative RadioTherapy After Complete Resection of Thymoma—a French DELPHI Consensus Initiative;Journal of Thoracic Oncology;2024-07
2. Advances in Lung Cancer Particle Radiotherapy;Haigan;2024-04-20
3. Determining Risks and Treating of Radiation Pneumonitis After Thoracic Radiation;Complications of Cancer Therapy: Best Practices in Prevention and Management;2024
4. Proton Radiation Therapy;Fundamentals of Radiation Oncology;2024
5. Factors related to fixedness after transbronchial fiducial marker placement for image-guided proton therapy: A retrospective study;Respiratory Investigation;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3